Experienced in Li-Fraumeni Syndrome

Dr. Kimberly L. Levinson

Gynecologic Oncology | Oncology
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
Accepting New Patients
Offers Telehealth
Experienced in Li-Fraumeni Syndrome
Johns Hopkins University
600 N Wolf St, 
Baltimore, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kimberly Levinson is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Levinson is rated as an Experienced provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Endometrial Cancer, Testicular Yolk Sac Tumor, Ovarian Cancer, Hysterectomy, and Lymphadenectomy. Dr. Levinson is currently accepting new patients.

Her clinical research consists of co-authoring 64 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Licenses
Obstetrics & Gynecology in MD
Hospital Affiliations
Greater Baltimore Medical Center
The Johns Hopkins Hospital
Languages Spoken
English
American Sign Language
Spanish
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

JOHNS HOPKINS UNIVERSITY
600 N Wolf St, Baltimore, MD 21287
Other Locations
GREATER BALTIMORE MEDICAL CENTER INC
6569 N Charles St, 307 Gyn Fertility Gbmc, Baltimore, MD 21204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel
Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel
Enrollment Status: Completed
Publish Date: July 23, 2024
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Carboplatin, Paclitaxel
Study Phase: Phase 3
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
Enrollment Status: Completed
Publish Date: November 16, 2021
Intervention Type: Procedure, Drug, Other
Study Phase: Early Phase 1
A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3)
Enrollment Status: Completed
Publish Date: April 28, 2021
Intervention Type: Drug
Study Phase: Phase 1
View 6 Less Clinical Trials

64 Total Publications

Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria.
Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria.
Journal: JCO global oncology
Published: October 08, 2025
Similar Doctors
Distinguished in Li-Fraumeni Syndrome
Dr. Carol K. Tweed
Oncology | Hematology Oncology
Distinguished in Li-Fraumeni Syndrome
Dr. Carol K. Tweed
Oncology | Hematology Oncology

Maryland Oncology Hematology PA

7704 Matapeake Business Dr, Suite 200, 
Brandywine, MD 
 (45.4 miles away)
301-812-3900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Carol Tweed is an Oncologist and a Hematologist Oncology provider in Brandywine, Maryland. Dr. Tweed is rated as a Distinguished provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, and Li-Fraumeni Syndrome. Dr. Tweed is currently accepting new patients.

Advanced in Li-Fraumeni Syndrome
Dr. Teresa P. Diaz-Montes
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in Li-Fraumeni Syndrome
Dr. Teresa P. Diaz-Montes
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

St Paul Place Specialists Inc

301 Saint Paul St, 
Baltimore, MD 
 (1.2 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Teresa Diaz-Montes is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Diaz-Montes is rated as a Distinguished provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Endometrial Cancer, Endometrial Stromal Sarcoma, Vulvar Cancer, Hysterectomy, and Ureteroscopy. Dr. Diaz-Montes is currently accepting new patients.

Advanced in Li-Fraumeni Syndrome
Dr. Dwight D. Im
Gynecologic Oncology | Oncology
Advanced in Li-Fraumeni Syndrome
Dr. Dwight D. Im
Gynecologic Oncology | Oncology

St Paul Place Specialists Inc

7602 Belair Rd, 
Baltimore, MD 
 (6.2 miles away)
410-663-8100
Languages Spoken:
English, Korean
See accepted insurances
Accepting New Patients

Dwight Im is a Gynecologic Oncologist and an Oncologist in Baltimore, Maryland. Dr. Im is rated as a Distinguished provider by MediFind in the treatment of Li-Fraumeni Syndrome. His top areas of expertise are Rectocele, Endometrial Cancer, Endometrial Stromal Sarcoma, Hysterectomy, and Oophorectomy. Dr. Im is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Levinson's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile